HomeREGULATORY
REGULATORY

Just Months after Big Re-Pricing, Opdivo Faces 37.5% Price Slash on Dose Change
(Aug.22.2018)

Less than a year after a major price cut in April, Ono Pharmaceutical’s PD-1 inhibitor Opdivo (nivolumab) is facing a 37.5% slash due to its dosage change for its main lung cancer indication under a new “quarterly re-pricing” rule introduced this year, with the reduction slated to be effective on November 1 ...
(LOG IN FOR FULL STORY)

News Calendar